View in EDS

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study

Saved in:
Bibliographic Details
Title: Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Authors: Patrikidou, Anna1 (AUTHOR), Saieva, Calogero2 (AUTHOR), Lee-Ying, Richard3 (AUTHOR), Nuzzo, Pier Vitale4 (AUTHOR), Zarif, Talal El5 (AUTHOR), McClure, Heather5 (AUTHOR), Davidsohn, Matthew5 (AUTHOR), Eid, Marc5 (AUTHOR), Spinelli, Gian Paolo6 (AUTHOR), Catalano, Fabio7 (AUTHOR), Cremante, Malvina7 (AUTHOR), Fotia, Giuseppe8 (AUTHOR), Rossetti, Sabrina9 (AUTHOR), Valenca, Loana10 (AUTHOR), Vauchier, Charles11 (AUTHOR), Ottanelli, Carlotta12 (AUTHOR), Andrade, Livia10 (AUTHOR), Gennusa, Vincenzo13 (AUTHOR), Mestre, Ricardo Pereira14 (AUTHOR), Fornarini, Giuseppe7 (AUTHOR)
Source: Clinical Genitourinary Cancer. Dec2024, Vol. 22 Issue 6, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:15587673
DOI:10.1016/j.clgc.2024.102230